You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Thiazolidinediones Articles
Popular Thiazolidinediones Articles
Highly Recommended Thiazolidinediones Articles
Send a link to this page to your friends and colleagues.
The latest clinical guidelines for treating type 2 diabetes from the American College of Physicians (ACP) indicate that when diet, exercise, and weight loss fail to control blood sugar levels in early type 2 patients, physicians should prescribe metformin as the first drug therapy.
The ACP recommends that metformin be prescribed initially as a stand-alone monotherapy. As the disease progresses and metformin's initial efficacy begins to fade, doctors can add a second drug.
To develop its recommendations, the ACP examined 44 years of data on the performance of all FDA-approved oral medications for type 2s, from 1966 through early 2010. The drug types reviewed included metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, and GLP-1 receptor antagonists.
The ACP discovered that while most of the drugs have similar effects in reducing blood sugar levels, metformin is the most effective in doing so, whether used alone or in combination. The ACP also found that metformin helps reduce body weight and improve cholesterol counts.
The study reinforces what has become a common practice among healthcare professionals who deal with type 2 diabetes. Metformin, first developed in the 1970s, has become the preferred first medication prescribed for patients with early-stage type 2. It has also become a common therapy for prediabetes patients and people with metabolic syndrome who are attempting to stave off type 2 diabetes.
The ACP noted that there was insufficient evidence to discern any difference in the efficacy of type 2 drugs among adults based on age, sex, or ethnicity.
Categories: ACP, American College of Physicians, Blood Sugar Levels, Diabetes, Diabetes, DPP-4 Inhibitors, Early-Stage Type 2, FDA, GLP-1 Receptor Antagonists, Meglitinides, Metformin, Oral Medications, Sulfonylureas, Thiazolidinediones, Type 2 Diabetes, Type 2 Issues, Type 2 Patients
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.

Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...